A new drug has shown major promise on its ability to suppress advanced lung cancer into a manageable chronic disease, according to researchers from the Chinese University of Hong Kong’s Faculty of Medicine (CU Medicine).
In a global clinical trial spanning seven years, CU Medicine enrolled 296 advanced lung cancer patients with the ALK — Anaplastic Lymphoma Kinase — genomic mutation…
阅读更多（Read More）